Vaxcyte, Inc. (PCVX) Stock
PCVX has an Alpha Score of 31 out of 100 (poor), computed on Nov 4, 2026 from 2 of 4 sub-scores. 3 members of Congress disclosed 9 trades in PCVX since 2022: 7 purchases and 2 sales, most recently Gilbert Cisneros (purchase, Jul 16, 2026). 5 of the hedge funds AlphaScala tracks reported PCVX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $110.56M. Company insiders reported 0 open-market buys and 10 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
What is PCVX's Alpha Score?
How it works →Alpha Score of 31 reflects weak overall profile with weak momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Vaxcyte, Inc. (PCVX)?
Most recent: Gilbert Cisneros (purchase, Jul 16, 2026); records start Nov 8, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Gil Cisneros D-CA · House | 2026-07-16 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-05-13 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-05-12 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-04-28 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-04-15 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-04-14 | purchase | $1k – $15k |
| Jefferson Shreve R-IN · House | 2025-03-05 | sale | $15k – $50k |
| Chris Jacobs R-NY · House | 2022-12-12 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all PCVX political trades →Which hedge funds own PCVX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.90M | $110.56M | -34% |
| Maverick Capital Lee Ainslie | 1.61M | $93.78M | +17% |
| Millennium Management Israel Englander | 137K | $7.94M | -53% |
| Bridgewater Associates Ray Dalio | 50K | $2.92M | +289% |
| Renaissance Technologies Jim Simons (founder) | 20K | $1.14M | -64% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Vaxcyte, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SELL | 18.0K | $1.6M |
| Oct 5, 26 | Cowan Elvia | SVP, Finance & CAO | SELL | 19.0K | $1.6M |
| Oct 1, 26 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SELL | 2.2K | $122K |
| Oct 1, 26 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SELL | 95 | $5K |
| Sep 9, 26 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SELL | 1.3K | $79K |
| Sep 4, 26 | Wassil Jim | EVP, Chief Scientific Ofc, COO | SELL | 1.4K | $84K |
| Sep 1, 26 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 1.5K | $94K |
| Sep 1, 26 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 713 | $44K |
| Sep 1, 26 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 924 | $56K |
| Sep 1, 26 | Wassil Jim | CHIEF OPERATING OFFICER | SELL | 303 | $19K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are PCVX's key statistics?
Key statistics as of Nov 1, 2026
PCVX price chart
Powered by TradingViewWhat does Vaxcyte, Inc. do?
Vaxcyte Inc. is a biotechnology company focused on developing innovative vaccines for preventing infectious diseases. The primary objective of the company is to create safer and more effective vaccines using its proprietary cell-free protein synthesis platform, a groundbreaking technology that aims to enhance vaccine design and production efficiency. Vaxcyte’s developments are particularly significant in the pharmaceutical industry, as they target diseases with high unmet medical needs and those that pose significant global health challenges. By addressing vaccine efficacy and safety, Vaxcyte contributes to the broader health sector’s mission to improve public health outcomes. The company's efforts are crucial in advancing preventative healthcare measures, providing new solutions for vaccine-preventable diseases. As part of the larger biotechnology market, Vaxcyte Inc. plays a pivotal role in fostering innovation that could redefine standards for vaccine development, offering potential breakthroughs through its cutting-edge approaches.